Abstracts differentiated: 13 £ MRS5 < 26, 26 £ MRS4 < 62, and 62 £ MRS(0 + 1 + 2 + 3) £91. Each wave, baseline, 1, 3, and 6 month showed similar trend in cut-offs. CON-CLUSIONS: The categorization scheme developed can serve as a crosswalk between measures. However, due to the ceiling effect of the BI and M-FIM, the crosswalk could not be completed for all six distinct levels in the MRS. No apparent variation over time in the categorization scheme was observed. 
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OUTCOMES OF AN INTERVENTION TO
OBJECTIVES:
To evaluate an intervention to reduce inappropriate use of key antibiotics. METHODS: The intervention was a policy for appropriate use of Alert Antibiotics (carbapenems, glycopeptides, amphotericin, ciprofloxacin, linezolid, piperacillin tazobactam and third generation cephalosporins) implemented through concurrent, patient specific feedback by clinical pharmacists in a tertiary university hospital. Statistical significance and effect size were calculated by segmented regression analysis of interrupted time series of drug use and cost for two years before and after the intervention started. RESULTS: Use of Alert Antibiotics increased before the intervention started but decreased steadily thereafter. The changes in slope of the time series were 0.27 Defined Daily Doses/100bed days per month (95% CI 0.19-0.34 P < 0.0001) and £1908 per month (95% CI £1238-£2578 P < 0.0001). The cost of development, dissemination and implementation of the intervention (£20,133) was well below the most conservative estimate of the reduction in cost (£133,296), which is the lower 95% CI of effect size assuming that cost would not have continued to increase without the intervention. However, if use had continued to increase, the difference between predicted and actual cost of Alert Antibiotics was £572,448 (95% CI £435,696-£709,176 P < 0.0001) over the 24 months after the intervention started. CONCLUSIONS: Segmented regression analysis of pharmacy stock data is a simple, practical and robust method for measuring the impact of interventions to change prescribing. The Alert Antibiotic monitoring programme was associated with significant decreases in total use and cost in the two years after the programme. In our hospital the value of the data far exceeded the cost of processing and analysis.
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DIFFERENCES IN PATIENT BURDEN BETWEEN ENDOANAL MRI, DEFECOGRAPHY AND ANORECTAL FUNCTIONAL TESTING FOR PATIENTS WITH FAECAL INCONTINENCE
Deutekom M, Dijkgraaf MGW, Bossuyt PM, Terra MP, Dobben AC, Stoker J Academic Medical Center, Amsterdam, Netherlands OBJECTIVE: The work-up of patients with faecal incontinence can contain multiple tests, including endoanal MRI, defecography and anorectal functional testing. In the search of an optimal diagnostic work-up it is generally accepted that costs and effectiveness data are required. However, test differences could also be found in the amount of patient burden. The aim of this study is to evaluate the burden of tests used in the evaluation of patients with faecal incontinence. METHODS: Consenting consecutive patients underwent a standard testing protocol. Burden of testing was evaluated with a selfadministered questionnaire. The main variables were anxiety, embarrassment, pain and discomfort, all measured on a 1 (low) to 5 (high) point-scale. An overall burden score was calculated by summing the scores of the four variables. In addition, patients were asked to rank the three tests from least to most inconvenient and to indicate whether they would advice the tests to friends/relatives. Statistical analysis was performed with Friedman tests. RESULTS: Data from 93 patients (14 men; mean age 60 (range 32 to 80)) were analysed. There were between test differences in terms of total burden, pain (less for MRI than with anorectal functional testing (p < 0.05)) and discomfort (lower for MRI compared to defecography (p < 0.05)), as well as embarrassment (lowest score for MRI and highest for defecography). Overall, MRI was preferred more often than defecography and functional testing, with 71% of the patients scoring MRI as least inconvenient. Patients would advice all tests to a friend/relative. CONCLUSION: This study shows significant differences in patient burden for medical tests to evaluate faecal incontinence, although this burden seems to be accepted by all participants. When evaluating medical tests for patients with incontinence, these findings can complement data on costs and effectiveness to develop the optimal strategy, minimizing total patient burden while achieving adequate diagnostic effectiveness. 
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A METHOD FOR IDENTIFICATION OF FRONTIER PRACTICE IN DIABETES CARE
